FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

CityNews Toronto

WASHINGTON (AP) — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic.

Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older.

The FDA […] ...

전문 보기

이 뉴스, 독자들은 어떻게 느꼈나요?

첫 반응을 남겨보세요

로그인하면 감정 반응에 참여할 수 있어요.

공식 발표 ↔ 진영별 보도

진보 성향 25%중도 성향 50%보수 성향 25%

1건2건1건

공식 발표 (3건) — 공공 라이선스 원문 직접 열람

🇺🇸Federal Register Notices

Agency Information Collection Activities; Proposed Collection; Comment Request; Extralabel Drug Use in Animals

🇺🇸Federal Register Notices

SpecGx LLC; Withdrawal of Approval of Abbreviated New Drug Application for Methylphenidate Hydrochloride Extended-Release Tablets, 27 Milligrams, 36 Milligrams, and 54 Milligrams

🇺🇸Federal Register Notices

Advisory Committee; Science Board to the Food and Drug Administration; Renewal

진보 성향1

🇬🇧The Guardian World

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

중도 성향2

🇨🇦CityNews Toronto

보는 중

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

🇺🇸The Hill

FDA vaccine panel set to review Moderna mRNA flu shot

보수 성향1